BGA 002
Alternative Names: BGA-002Latest Information Update: 11 Feb 2022
At a glance
- Originator BIOGENERA
- Class Antineoplastics
- Mechanism of Action Genetic transcription inhibitors; Proto-oncogene protein c-myc inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neuroblastoma; Small cell lung cancer; Soft tissue sarcoma
Most Recent Events
- 11 Feb 2022 Preclinical trials in Small cell lung cancer in Italy (unspecified route) (Biogenera pipeline, February 2022)
- 11 Feb 2022 Preclinical trials in Soft tissue sarcoma in Italy (unspecified route) (Biogenera pipeline, February 2022)
- 11 Feb 2022 BGA 002 receives Orphan Drug status for Small cell lung cancer in USA (Biogenera pipeline, February 2022).